Oncology Development Programme, ODP2 Part 3: DEVELOP
Published on 25/04/2023
Calling UK innovators with an oncology innovation that would benefit from accelerated translation through development – Access the dedicated funding and unique insights you need from across the global oncology ecosystem by participating in ODP2.
Submit your application for Part 3: DEVELOP of the fully funded ODP2 programme BEFORE 21 May 2023.
This intensive, 5-month module running from June to October 2023 will give you access to relevant expertise and resources to contribute towards development of a de-risked and costed development plan for your innovation. The programme is supported by unique insights from a collaboration of leading global pharma companies, CROs, and subject matter experts in residence from across the global oncology R&D ecosystem.
Throughout the intensive 20-week module, we support you to develop compelling value propositions to enhance your chances of securing investment. To date, participants in the previous programme (ODP1, run in 2021) have raised in excess of £45 million.
With the time to dedicate to participating in ODP2 Part 3: DEVELOP, the eight selected innovations will have dedicated funding and unique access to bespoke expert scientific review, clinical study design, technical gap analysis, financial / business value modelling and integrated project planning.
Developed and fully funded in collaboration with Cancer Research Horizons , Lean Life Science is proud to be delivering Part 3: DEVELOP of ODP2, their latest Oncology Development Programme.
Note: ODP2 is only open to the UK-based academic community and early-stage companies with an oncology-focused innovation (including therapeutic of any modality, diagnostic & biomarker, digital health, medtech, platform technology).
